09-0830
Ethyl alcohol, pure
≥99.5%, for residue analysis, JIS 300
Synonym(s):
Ethyl alcohol
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
CH3CH2OH
CAS Number:
Molecular Weight:
46.07
PubChem Substance ID:
UNSPSC Code:
15101802
EC Number:
200-578-6
MDL number:
Beilstein/REAXYS Number:
1718733
Product Name
Ethanol, JIS 300, ≥99.5%, suitable for residue analysis
agency
JIS 300
vapor density
1.59 (vs air)
vapor pressure
44.6 mmHg ( 20 °C)
assay
≥99.5%
form
liquid
autoignition temp.
683 °F
expl. lim.
19 %, 60 °F
availability
available only in Japan
refractive index
n20/D 1.3600 (lit.)
pH
7.0 (20 °C, 10 g/L)
bp
78 °C (lit.)
mp
−114 °C (lit.)
suitability
suitable for residue analysis
format
neat
SMILES string
CCO
InChI
1S/C2H6O/c1-2-3/h3H,2H2,1H3
InChI key
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
Other Notes
1Distribution and use of ethyl alcohol in Switzerland require a license from the Swiss Federal Alcohol Administration
Still not finding the right product?
Explore all of our products under Ethanol
signalword
Danger
hcodes
Hazard Classifications
Eye Irrit. 2 - Flam. Liq. 2
Storage Class
3 - Flammable liquids
wgk
WGK 1
flash_point_f
55.4 °F - closed cup
flash_point_c
13 °C - closed cup
ppe
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ioannis Lignos et al.
Small (Weinheim an der Bergstrasse, Germany), 11(32), 4009-4017 (2015-05-23)
The early-time kinetics (<1 s) of lead sulfide (PbS) quantum dot formation are probed using a novel droplet-based microfluidic platform, which allows for high-throughput and real-time optical analysis of the reactive process with millisecond time resolution. The reaction platform enables
Ross B Mounsey et al.
Experimental neurology, 273, 36-44 (2015-08-06)
Parkinson's disease (PD) is a common chronic neurodegenerative disorder, usually of idiopathic origin. Symptoms including tremor, bradykinesia, rigidity and postural instability are caused by the progressive loss of dopaminergic neurons in the nigrostriatal region of the brain. Symptomatic therapies are
Gian Marco Leggio et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(8), 2017-2028 (2014-03-04)
Mesolimbic dopamine (DA) controls drug- and alcohol-seeking behavior, but the role of specific DA receptor subtypes is unclear. We tested the hypothesis that D3R gene deletion or the D3R pharmacological blockade inhibits ethanol preference in mice. D3R-deficient mice (D3R(-/-)) and